Galderma Laboratories, L.P.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$86Mgeneral payments (2019-2025)
$347Kresearch payments (2019-2025)
38,161clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Nemluvio $11M associated (2023-2025)
- Aklief $4.7M associated (2023-2025)
- Epsolay $2.3M associated (2023-2025)
- Oracea $2.2M associated (2023-2025)
- Twyneo $2.2M associated (2023-2025)
- Dysport $288K associated (2023-2025)
- Epiduo $2,016 associated (2023-2025)
- Tri-Luma $320 associated (2023-2025)
- Oracea Ag $66.34 associated (2023-2025)
- Capex $41.05 associated (2023-2025)
- Differin $22.56 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Sabrina Fabi | San Diego, CA | Procedural Dermatology | $1,118,292.72 |
| George Baxter | Seattle, WA | Adult Health (Nurse Practitioner) | $766,318.99 |
| Lauren Meade | Lexington, KY | Physician Assistant | $655,193.72 |
| Christopher Surek | Cleveland, OH | Plastic Surgery | $638,188.38 |
| Kian Karimi | Los Angeles, CA | Facial Plastic Surgery | $615,230.64 |
| Steven Weiner | Santa Rosa Beach, FL | $613,947.47 | |
| Daryoush Saadat | Valencia, CA | Facial Plastic Surgery | $613,545.86 |
| Nina Deep | Westerville, OH | Internal Medicine | $613,217.82 |
| Steven Dayan | Chicago, IL | Plastic Surgery | $588,237.52 |
| Yula Indeyeva | Austin, TX | Otolaryngology/Facial Plastic Surgery | $579,158.59 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.